背景:我们旨在全面阐明抗IL-5药物的安全性,并查明其上市后阶段可能出现的潜在安全性问题。
方法:两名研究人员对PubMed进行了全面搜索,EMBASE,WebofScience,和Cochrane图书馆从成立到2022年9月。此外,我们调查了FDAAE报告系统中与抗IL-5药物相关的上市后不良事件(AE)报告.结果满足比例报告率标准和贝叶斯置信度传播神经网络。
结果:我们在分析中纳入了24项已发表的研究。抗IL-5治疗组的AE发生率与安慰剂组相当,严重不良事件发生率明显较低。常见的不良事件是哮喘,鼻咽炎,头痛,上呼吸道感染(URTI),还有支气管炎.上市后数据包括28,478例与可疑药物相关的病例报告和75例影响16个系统器官类别的可疑安全性观察。新的可疑观察包括不完全的治疗产品效果,URTIS,与美泊利单抗相关的报告中的肺部肿块。与mepolizumab和benralizumab相关的报告也表明设备使用技术不正确的问题和产品问题。
结论:个体抗IL-5药物的安全性在很大程度上与其产品说明书相匹配。我们发现了设备使用不当等问题,产品问题,和URTIs是美泊利单抗和贝那利珠单抗的潜在担忧。此外,所有抗IL-5药物均显示治疗效果不完全的迹象.
BACKGROUND: We aimed to clarify comprehensively the safety profiles of anti-IL-5 drugs and pinpoint potential safety concerns that may arise in their post-marketing phase.
METHODS: Two researchers conducted comprehensive searches of PubMed, EMBASE, Web of Science, and the Cochrane Library from inception to September 2022. Additionally, we investigated the FDA AE Reporting System for post-marketing adverse event (AE) reports related to anti-IL-5 drugs. The outcomes fulfilled the proportional reporting rate criteria and the Bayesian confidence propagation neural network.
RESULTS: We included 24 published studies in our analysis. The anti-IL-5 treatment group showed an incidence of AEs comparable to the placebo group, and it exhibited a significantly lower frequency of serious AEs. Common AEs were asthma, nasopharyngitis, headache, upper respiratory tract infection (URTI), and bronchitis. The post-marketing data included 28,478 case reports associated with the suspect drugs and 75 suspect safety observations affecting 16 system organ classes. New suspect observations included incomplete therapeutic product effect, URTIs, and pulmonary mass in reports related to mepolizumab. Reports associated with mepolizumab and benralizumab also indicated issues with incorrect technique in device usage and product issues.
CONCLUSIONS: Individual anti-IL-5 drugs\' safety profiles largely matched their product inserts. We identified issues like improper device usage, product issue, and URTIs as potential concerns for mepolizumab and benralizumab. Additionally, all anti-IL-5 drugs showed signs of incomplete therapeutic effects.